Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | F3 | P13726 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | CCNK | O75909 | 1/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL621372 | 0.71 | TGFBR1 (0.44) | KDM4EALDH1A1HPGDCDK1PIM1 | |
| SCHEMBL19413409 | 0.70 | ENPP2 (0.48) | ALDH1A1TSHRTYMSFGFR1MCL1 | |
| SCHEMBL14820311 | 0.69 | KDM4E (0.39) | KDM4EALDH1A1HPGDTSHRTYMS | |
| SCHEMBL21642420 | 0.68 | TDP1 (0.44) | KDM4EALDH1A1HPGDCDK1PIM1 | |
| SCHEMBL24478696 | 0.65 | ALDH1A1 (0.35) | KDM4EALDH1A1HPGDCDK1PIM1 | |
| SCHEMBL1976000 | 0.65 | QPCT (0.45) | KDM4EALDH1A1HPGDTSHRFGFR1 | |
| SCHEMBL1976001 | 0.65 | QPCT (0.55) | KDM4EMAPT | |
| SCHEMBL4540271 | 0.65 | CYP1A2 (0.63) | KDM4ETYMS | |
| SCHEMBL8637909 | 0.65 | AKR1C3 (0.52) | KDM4EALDH1A1HPGDTSHRTYMS | |
| SCHEMBL8733538 | 0.64 | QPCT (0.44) | KDM4EALDH1A1HPGDTSHRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542297-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11530237-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220220150-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220213137-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2022-07-07 | — | — | US | disclosed |
| EP-3885352-A1 | A COMPOUND, COMPOSITIONS THEREOF AND THIS COMPOUND FOR USE IN METHODS OF TREATING CNS DISORDERS | Sage Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20200392177-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10577390-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20170240589-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170240589-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2017-08-24 | — | — | US | disclosed |
| WO-2016061527-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530237-B2 | Compositions and methods for treating CNS disorders | ADRA1B, ADRA2B, ADRA1A | DYRK1A 2150/4885KDM4E 1272/4885ALDH1A1 615/4885 |
| US-10577390-B2 | Compositions and methods for treating CNS disorders | ADRA1B, ADRA2B, GRIN2B | DYRK1A 1943/4885KDM4E 1293/4885ALDH1A1 578/4885 |
| US-20220220150-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | ADRA1B, ADRA2B, ADRA1A | DYRK1A 2139/4885KDM4E 1264/4885ALDH1A1 622/4885 |
| US-20200392177-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | ADRA1B, ADRA2B, ADRA1A | DYRK1A 2150/4885KDM4E 1272/4885ALDH1A1 615/4885 |
| US-20170240589-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | ADRA1B, ADRA2B, ADRA1A | DYRK1A 1958/4885KDM4E 1215/4885ALDH1A1 573/4885 |
| US-11542297-B2 | Compositions and methods for treating CNS disorders | ADRA1B, ADRA2B, ADRA1A | DYRK1A 2139/4885KDM4E 1264/4885ALDH1A1 622/4885 |
| US-20220213137-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | ADRA1B, ADRA2B, ADRA1A | DYRK1A 2044/4885KDM4E 1116/4885ALDH1A1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.